Treatment of Classical Hodgkin Lymphoma in Children and Adolescents with Relapsed or Refractory Disease
This protocol is for patients age 18 years or younger who have classical Hodgkin lymphoma that has returned after initial treatment, or that did not respond to initial treatment at all.
Clinical scenario: Children and adolescents (age 18 years or younger) with classical Hodgkin lymphoma that has relapsed (come back after treatment) or is refractory (did not respond to initial treatment).
Treatment approach: Management in this pediatric and adolescent setting involves transplant-based strategies, including the use of donor stem cells, with additional options depending on prior treatment history.
The full regimen — including all treatment options, eligibility criteria, and sequencing — is available in the complete protocol.
References
- Treatments for Children and Adolescents with Relapsed or Refractory Classical Hodgkin Lymphoma.
- Treatment options for children and adolescents whose disease has relapsed (come back after treatment) or is refractory (did not respond to initial treatment).
- High-dose chemotherapy with allogeneic stem cell transplantation, which uses a donor's stem cells.